Streetbeat News

Analyst Ratings

CRL

Morgan Stanley analyst Ricky Goldwasser has maintained an Equal-Weight rating on Charles River (NYSE:CRL) and lowered the price target from $220 to $205.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:54 pm

BIIB

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Biogen (NASDAQ:BIIB) and raises the price target from $361 to $373.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:53 pm

PRPL

Wedbush analyst Seth Basham maintains an Outperform rating on Purple Innovation (NASDAQ:PRPL) but lowers the price target from $3 to $1.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:53 pm

BBY

Wedbush analyst Seth Basham maintains a Neutral rating on Best Buy Co (NYSE:BBY) and lowers the price target from $82 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:51 pm

TWOU

Morgan Stanley analyst Josh Baer has maintained an Equal-Weight rating on 2U (NASDAQ:TWOU) and lowered the price target from $3 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:50 pm

BUR

Wedbush analyst David Chiaverini maintains an Outperform rating on Burford Capital (NYSE:BUR) but lowers the price target from $20 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:49 pm

WD

Wedbush analyst Jay McCanless has maintained an Outperform rating on Walker & Dunlop (NYSE:WD), but lowered the price target from $105 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:47 pm

ZD

Susquehanna analyst Shyam Patil maintains a positive outlook on Ziff Davis (NASDAQ:ZD), but has lowered the price target from $120 to $90.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:47 pm

FIGS

MOTS

TTD

Figs shares rose premarket due to investor Ron Baron discussing the stock on CNBC. The Trade Desk shares fell after issuing Q4 revenue guidance below estimates. Motus GI announced the first upper GI patient procedure for FDA cleared Pure-Vu® EVS Gastro, causing a significant rise in its shares.

Portfolio Pulse from ryanfaloona@benzinga.com

November 10, 2023 | 1:42 pm

EWTX

Wedbush analyst Laura Chico maintains an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) but lowers the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:35 pm